{"id":"granisetron-and-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL1237080","moleculeType":"Small molecule","molecularWeight":"348.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Granisetron is a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Dexamethasone is a corticosteroid that reduces inflammation and potentiates antiemetic activity through multiple pathways. Together, this combination targets chemotherapy-induced nausea and vomiting (CINV) through complementary mechanisms.","oneSentence":"Granisetron blocks 5-HT3 receptors to prevent nausea and vomiting, while dexamethasone suppresses inflammatory cytokines and enhances antiemetic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:19.339Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in cancer patients receiving emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT00343460","phase":"PHASE3","title":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2006-06","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1428},{"nctId":"NCT02106494","phase":"PHASE3","title":"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2014-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":942},{"nctId":"NCT07360431","phase":"PHASE4","title":"Granisetron Combined With Dexamethasone or Metoclopramide for PONV Prevention After Laparoscopic Cholecystectomy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03","conditions":"Postoperative Nausea and Vomiting (PONV)","enrollment":102},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":414},{"nctId":"NCT04150614","phase":"PHASE4","title":"BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2020-05-14","conditions":"Nausea With Vomiting Chemotherapy-Induced","enrollment":90},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT06224894","phase":"NA","title":"The Effect of Music Therapy on Nausea, Vomiting and Anxiety Levels in Children","status":"UNKNOWN","sponsor":"Bilecik Seyh Edebali Universitesi","startDate":"2024-02-01","conditions":"Music Therapy, Nausea, Anxiety","enrollment":80},{"nctId":"NCT05711823","phase":"PHASE3","title":"Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2024-07-01","conditions":"Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT05408676","phase":"NA","title":"Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-06-10","conditions":"Mammary Cancer, PONV","enrollment":198},{"nctId":"NCT06043336","phase":"PHASE4","title":"Palonosetron vs Combination of Granisetron and Dexamethasone in Preventing PONV in Laparoscopic Cholecystectomy.","status":"COMPLETED","sponsor":"Universiti Kebangsaan Malaysia Medical Centre","startDate":"2018-05-10","conditions":"Postoperative Nausea and Vomiting","enrollment":134},{"nctId":"NCT01298193","phase":"PHASE4","title":"Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2011-05","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT05200806","phase":"PHASE4","title":"A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2022-02-07","conditions":"Analgesia, Post-Operative Pain, Breakthrough Pain","enrollment":25},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05325190","phase":"PHASE2","title":"Granisetron Transdermal Patch System for Prevention of CINV by CapeOX","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-10-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":57},{"nctId":"NCT05230654","phase":"NA","title":"Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs","status":"UNKNOWN","sponsor":"Shanghai Children's Medical Center","startDate":"2022-02-01","conditions":"Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients","enrollment":120},{"nctId":"NCT01346267","phase":"NA","title":"Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2011-05","conditions":"Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":187},{"nctId":"NCT04836819","phase":"NA","title":"Analgesia Management in Bariatric Surgery","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2021-04-08","conditions":"Morbid Obesity, Bariatric Surgery Candidate, Pain","enrollment":78},{"nctId":"NCT04912271","phase":"PHASE3","title":"Granisetron Transdermal Patch for Prophylaxis of Delayed CINV","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-06-10","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":140},{"nctId":"NCT04873284","phase":"NA","title":"Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients","status":"UNKNOWN","sponsor":"Shanghai Children's Medical Center","startDate":"2021-05-01","conditions":"Chemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients","enrollment":120},{"nctId":"NCT04570592","phase":"PHASE2","title":"Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting","status":"UNKNOWN","sponsor":"Universiti Sains Malaysia","startDate":"2020-10-01","conditions":"PONV","enrollment":126},{"nctId":"NCT01633203","phase":"","title":"Observational Study of Perioperative Chemotherapy in Gastric Cancer","status":"COMPLETED","sponsor":"Grupo Oncologico Cooperativo Chileno de Investigation","startDate":"2010-08","conditions":"Gastric Cancer","enrollment":61},{"nctId":"NCT03313557","phase":"PHASE1","title":"AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-27","conditions":"Solid Tumors","enrollment":48},{"nctId":"NCT03434340","phase":"NA","title":"Aromatherapy for Prevention of Intrathecal Morphine Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Universiti Kebangsaan Malaysia Medical Centre","startDate":"2018-06-26","conditions":"Post Operative Nausea and Vomiting","enrollment":155},{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":"Postoperative Nausea and Vomiting","enrollment":27034},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT01364805","phase":"PHASE1","title":"New Treatment Option for Pancreatic Cancer","status":"COMPLETED","sponsor":"Jeanne Drisko, MD, CNS, FACN","startDate":"2011-04","conditions":"Pancreatic Cancer","enrollment":14},{"nctId":"NCT01275664","phase":"NA","title":"Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"2011-06","conditions":"Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma","enrollment":4},{"nctId":"NCT03061396","phase":"NA","title":"The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints","status":"UNKNOWN","sponsor":"Tianjin University of Traditional Chinese Medicine","startDate":"2017-02-17","conditions":"Electro-acupuncture, Chemotherapy-induced Nausea and Vomiting","enrollment":208},{"nctId":"NCT00952341","phase":"PHASE3","title":"Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-25","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":421},{"nctId":"NCT00272285","phase":"PHASE3","title":"A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-01","conditions":"Vomiting, Nausea","enrollment":287},{"nctId":"NCT02441894","phase":"PHASE4","title":"Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04","conditions":"Prostate Cancer","enrollment":21},{"nctId":"NCT03017391","phase":"PHASE4","title":"Treatment Algorithm for Nausea and Vomiting in the Palliative Phase","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-01","conditions":"Nausea, Vomiting, Cancer","enrollment":20},{"nctId":"NCT01499849","phase":"PHASE3","title":"Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2012-02","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":532},{"nctId":"NCT00293384","phase":"NA","title":"Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2004-10","conditions":"Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor","enrollment":40},{"nctId":"NCT01500213","phase":"PHASE3","title":"Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2012-02","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":555},{"nctId":"NCT01500226","phase":"PHASE3","title":"Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2012-02","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":1369},{"nctId":"NCT01909856","phase":"PHASE2","title":"The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2011-10","conditions":"Cancer","enrollment":92},{"nctId":"NCT00475085","phase":"PHASE3","title":"Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"Joseph Roscoe","startDate":"2006-12","conditions":"Nausea","enrollment":1021},{"nctId":"NCT00450801","phase":"PHASE2","title":"R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-04","conditions":"Lymphoma","enrollment":22},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT02207660","phase":"","title":"Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2014-07","conditions":"Cervical Cancer","enrollment":30},{"nctId":"NCT00003213","phase":"PHASE3","title":"Drugs to Reduce the Side Effects of Chemotherapy","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"1996-05","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":267}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":133,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Granisetron and dexamethasone","genericName":"Granisetron and dexamethasone","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Granisetron blocks 5-HT3 receptors to prevent nausea and vomiting, while dexamethasone suppresses inflammatory cytokines and enhances antiemetic effects. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in cancer patients receiving emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}